© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Pierre Gholam, MD, reviews significant clinical trial data and treatment options for the management of unresectable HCC.
July 28th 2021
Pierre Gholam, MD, presents the case of a 61-year-old woman with hepatocellular carcinoma (HCC).
Dr Gholam, MD, provides expert analysis on the prognosis and treatment of a patient with unresectable HCC.
An expert in the treatment of HCC comments on first-line therapeutic options for patients with previously untreated, advanced HCC.
Dr Gholam reviews the study design and key data from the phase 3 REFLECT trial.
Gastroenterology expert, Dr Pierre Gholam, discusses the efficacy and safety data from the phase 3 IMbrave150 trial.
Pierre Gholam, MD, discusses future directions and novel therapeutic agents for the treatment of unresectable HCC.
A key opinion leader shares clinical practice pearls for the treatment of patients with unresectable HCC.